Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation
暂无分享,去创建一个
Todd R Golub | Kimberly Stegmaier | Andrew L Kung | Kenneth N Ross | T. Golub | K. Ross | K. Stegmaier | A. Kung | Ralph Mazitschek | R. Wright | Ralph Mazitschek | Renee D Wright | Cynthia K Hahn | Ian M Warrington | Cindy M Kanegai | Cindy M. Kanegai | C. Hahn | I. M. Warrington
[1] J. Cinatl,et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. , 1997, Anti-cancer drugs.
[2] S. Bates,et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. , 2002, Cancer research.
[3] T. Golub,et al. A method for high-throughput gene expression signature analysis , 2006, Genome Biology.
[4] K. Nilsson,et al. Phenotypic changes of human neuroblastoma cells in culture induced by 12‐O‐tetradecanoyl‐phorbol‐13‐acetate , 1981, International journal of cancer.
[5] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .
[6] A. Zambrano,et al. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells , 2007, Molecular Cancer Therapeutics.
[7] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[8] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[9] S. Shurin,et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. , 1991, Progress in clinical and biological research.
[10] P. Marks,et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. , 2000, Medical and pediatric oncology.
[11] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[12] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .
[13] P. Pandolfi,et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.
[14] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[15] S. Inoue,et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.
[16] P. Pandolfi,et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.
[17] S. Schreiber,et al. Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.
[18] P. Marks,et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.
[19] Todd R Golub,et al. Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.
[20] C. Johannessen,et al. Mechanisms of action of valproate: a commentatory , 2000, Neurochemistry International.
[21] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[22] C. Glass,et al. ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors , 1998, Molecular and Cellular Biology.
[23] C. Lanvers-Kaminsky,et al. Inhibitors of histone deacetylases as potential therapeutic tools for high‐risk embryonal tumors of the nervous system of childhood , 2007, International journal of cancer.
[24] L. Ries,et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .
[25] K. Nilsson,et al. Neuron specific enolase: a marker for differential diagnosis of neuroblastoma and Wilms' tumor. , 1982, Journal of pediatric surgery.
[26] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[27] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[28] R. Blaheta,et al. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. , 2002, International journal of oncology.
[29] P K Gessner,et al. Isobolographic analysis of interactions: an update on applications and utility. , 1995, Toxicology.
[30] J. Downing,et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.
[31] A. V. van Kuilenburg,et al. The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells. , 2004, Biochemical pharmacology.
[32] O. Brandt,et al. The benefit of disorder , 2006, Nature materials.
[33] D. Neuberg,et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P G Pelicci,et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.
[35] A. V. van Kuilenburg,et al. Histone deacetylase inhibitor BL1521 induces a G1‐phase arrest in neuroblastoma cells through altered expression of cell cycle proteins , 2005, FEBS letters.
[36] N. Sidell,et al. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. , 1982, Journal of the National Cancer Institute.